^
Association details:
| Biomarker: | EGFR exon 20 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ivesa (firmonertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
Excerpt:
...- Documented validated results from local or central testing (as designated by the Sponsor) of blood or tumor tissue confirming the presence of an EGFR exon 20 insertion mutation...
Trial ID:
Source:
Title:
Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation
Excerpt:
...- The treated patients must have radiological disease progression following the last anti-tumor therapy; and the treatment-naïve patients must have documented positive EGFR exon 20 insertion mutation by laboratory tests prior to enrollment;...
Trial ID:
More C2 evidence
Source:
Title:
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Excerpt:
...- Documented validated results confirming the presence of an Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutation in tumor tissue or blood from local or central testing....
Less C2 evidence
Source:
Title:
1210P Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)
Published date:
09/01/2021
Excerpt:
Furmonertinib has shown encouraging anti-tumor activity in EGFR 20ins NSCLC based on the preclinical data and the preliminary results of the phase Ib study without new safety signals. Further exploration of this phase Ib study is ongoing.
